Key Takeaways:
BOCOM International raised its 2026-28 net profit forecast for Asymchem Laboratories Inc. by as much as 14 percent, citing a strong first-quarter earnings beat and rising demand for its newer services.
The bank's analysts maintained a "Buy" rating on the contract development and manufacturing organization, noting that "emerging business orders continue to show high demand," according to their April 29 report.
The firm increased its price target for Asymchem's Hong Kong-listed H-shares to 136.6 HKD and its Shenzhen-listed A-shares to 159.2 RMB. The new targets reflect a 2-14 percent upward revision to the bank's adjusted net profit estimates for the 2026-2028 period.
The upgrade suggests growing confidence in Asymchem's ability to navigate a complex market, even as competitors like WuXi AppTec face geopolitical headwinds. Asymchem's focus on operational efficiency appears to be yielding results, allowing it to absorb currency fluctuations and a high comparison base from its small-molecule business.
BOCOM International's report highlighted the company's expanding order book for its late-stage and front-end businesses as a key factor supporting a positive long-term growth outlook. The bank sees Asymchem's forward-looking investments in high-growth sectors as providing strong certainty for sustained performance.
The robust first-quarter results came despite significant currency volatility and a challenging prior-year comparable for the company's established small-molecule drug services. The performance points to successful diversification and execution on its strategy to build out emerging capabilities, including biologics and clinical research services.
The positive analyst action for Asymchem provides a contrast to broader sentiment in the sector, where some contract research organizations have seen valuations compress. Investors will next look to the company's second-quarter results, expected in July, for confirmation that the demand momentum is continuing.
This article is for informational purposes only and does not constitute investment advice.
